Difference between revisions of "T-cell acute lymphoblastic leukemia"
| Line 57: | Line 57: | ||
|} | |} | ||
| − | Regimen is as per the GRAALL- | + | Regimen is as per the GRAALL-2003 Study. |
===References=== | ===References=== | ||
Revision as of 23:08, 10 December 2015
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
5 regimens on this page
6 variants on this page
|
Note that many of the regimens used to treat this disease are generic to acute lymphoblastic leukemia; this page contains regimens that are specific to T-cell acute lymphoblastic leukemia (a.k.a. T-cell lymphoblastic lymphoma when primarily nodal-based).
Induction therapy
AALL0434 Induction
| back to top |
Regimen
| Study | Evidence |
| Winter et al. 2015 | Phase II |
To be completed
References
- Winter SS, Dunsmore KP, Devidas M, Eisenberg N, Asselin BL, Wood BL, Leonard Rn MS, Murphy J, Gastier-Foster JM, Carroll AJ, Heerema NA, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatr Blood Cancer. 2015 Jul;62(7):1176-83. Epub 2015 Mar 8. link to original article PubMed
Pediatric-like GRAALL Induction
| back to top |
Regimen
| Study | Evidence |
| Lepretre et al. 2015 (GRAALL-LYSA LL03) | Phase II |
Regimen is as per the GRAALL-2003 Study.
References
- Lepretre S, Touzart A, Vermeulin T, Picquenot JM, Tanguy-Schmidt A, Salles G, Lamy T, Béné MC, Raffoux E, Huguet F, Chevallier P, Bologna S, Bouabdallah R, Benichou J, Brière J, Moreau A, Tallon-Simon V, Seris S, Graux C, Asnafi V, Ifrah N, Macintyre E, Dombret H. Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study. J Clin Oncol. 2015 Dec 7. [Epub ahead of print] link to early article PubMed
Relapsed/Refractory
Nelarabine (Arranon)
| back to top |
Regimen
| Study | Evidence |
| DeAngelo et al. 2007 (CALGB 19801) | Phase II |
See paper for details about the schedule.
- Nelarabine (Arranon) 1.5 g/m2 IV over 2 hours on days 1, 3, 5
21-day cycle x 3 to 4 cycles (or delayed for count recovery)
References
- DeAngelo DJ, Yu D, Johnson JL, Coutre SE, Stone RM, Stopeck AT, Gockerman JP, Mitchell BS, Appelbaum FR, Larson RA. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007 Jun 15;109(12):5136-42. Epub 2007 Mar 7. link to original article contains verified protocol PubMed